CL2016001327A1 - Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14) - Google Patents

Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14)

Info

Publication number
CL2016001327A1
CL2016001327A1 CL2016001327A CL2016001327A CL2016001327A1 CL 2016001327 A1 CL2016001327 A1 CL 2016001327A1 CL 2016001327 A CL2016001327 A CL 2016001327A CL 2016001327 A CL2016001327 A CL 2016001327A CL 2016001327 A1 CL2016001327 A1 CL 2016001327A1
Authority
CL
Chile
Prior art keywords
mif
combination therapy
divisional application
chemotherapeutic antibodies
chemotherapeutic
Prior art date
Application number
CL2016001327A
Other languages
English (en)
Inventor
Randolf Kerschbaumer
Hartmut Ehrlich
Friedrich Scheiflinger
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48625989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of CL2016001327A1 publication Critical patent/CL2016001327A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Telephonic Communication Services (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2016001327A 2012-04-16 2016-05-31 Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14) CL2016001327A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624964P 2012-04-16 2012-04-16
US201261668932P 2012-07-06 2012-07-06
US201361778094P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
CL2016001327A1 true CL2016001327A1 (es) 2017-01-06

Family

ID=48625989

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014002788A CL2014002788A1 (es) 2012-04-16 2014-10-16 Combinación de anticuerpos anti-mif y los quimioterapeuticos gemcitabina, cisplatina y/o doxorubicina; y su uso contra el cancer.
CL2016001327A CL2016001327A1 (es) 2012-04-16 2016-05-31 Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014002788A CL2014002788A1 (es) 2012-04-16 2014-10-16 Combinación de anticuerpos anti-mif y los quimioterapeuticos gemcitabina, cisplatina y/o doxorubicina; y su uso contra el cancer.

Country Status (16)

Country Link
US (1) US20150071942A1 (es)
EP (2) EP2838561A1 (es)
JP (2) JP2015514735A (es)
KR (2) KR20150027048A (es)
CN (2) CN104812411A (es)
AU (1) AU2013202693B2 (es)
BR (1) BR112014025855A8 (es)
CA (1) CA2869990A1 (es)
CL (2) CL2014002788A1 (es)
CO (1) CO7131377A2 (es)
HK (1) HK1206985A1 (es)
IL (2) IL235038A0 (es)
MX (1) MX2014012535A (es)
NZ (1) NZ628363A (es)
RU (2) RU2016117260A (es)
WO (1) WO2013156473A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150029017A (ko) 2012-07-10 2015-03-17 박스터 헬쓰케어 에스에이 항-mif 면역조직화학
CN106068456A (zh) * 2014-01-03 2016-11-02 百深有限责任公司 抗‑mif免疫组织化学
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JP4708510B2 (ja) * 1993-05-17 2011-06-22 サイトカイン ファーマサイエンシズ,インコーポレーテッド サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CA2572318A1 (en) * 2004-07-02 2006-01-12 Neutec Pharma Plc Treatment of cancer
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
US20090220521A1 (en) * 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies
WO2011090492A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
WO2013050457A1 (en) * 2011-10-07 2013-04-11 Baxter Healthcare S.A. Characterization of cho-mif gene and protein, and use thereof
US9958456B2 (en) * 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker

Also Published As

Publication number Publication date
HK1206985A1 (en) 2016-01-22
CN104812411A (zh) 2015-07-29
KR20150027048A (ko) 2015-03-11
JP2016175918A (ja) 2016-10-06
CO7131377A2 (es) 2014-12-01
BR112014025855A2 (es) 2017-06-20
NZ628363A (en) 2017-02-24
CN106139143A (zh) 2016-11-23
JP2015514735A (ja) 2015-05-21
IL235038A0 (en) 2014-12-31
KR20160049047A (ko) 2016-05-04
US20150071942A1 (en) 2015-03-12
IL245604A0 (en) 2016-06-30
EP3064221A1 (en) 2016-09-07
CL2014002788A1 (es) 2015-02-06
AU2013202693B2 (en) 2015-01-22
BR112014025855A8 (pt) 2017-07-25
RU2016117260A3 (es) 2018-10-23
RU2014145887A (ru) 2016-06-10
EP2838561A1 (en) 2015-02-25
MX2014012535A (es) 2015-04-10
RU2016117260A (ru) 2018-10-23
WO2013156473A1 (en) 2013-10-24
AU2013202693A1 (en) 2013-10-31
CA2869990A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
EA201892584A1 (ru) Системы и способы для изготовления объемных непрерывных волокон
PL2922850T3 (pl) Związki i sposoby ich stosowania
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
IL263320A (en) Anti-hemagglutinin antibodies and methods of use
IL228906A0 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
SI2858671T1 (sl) Formulacija protiteles
IL239587A0 (en) Re-ranking story content
LT2885010T (lt) Tautopatijos gydymo būdai
PL2812443T3 (pl) Przeciwciała CD47 i sposoby ich zastosowania
PL3978522T3 (pl) Ludzkie przeciwciała przeciwko fel d1 i sposoby ich stosowania
LT3354747T (lt) Neinvazinis naviko metilomos nustatymas iš plazmos
PL2544744T3 (pl) Element inhalatora
ZA201500593B (en) Activators of ampk and therapeutic uses thereof
LT3091141T (lt) Lengvesnės grindų plokštės iš mažiau medžiagų
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HUE055910T2 (hu) Anyag felhasználását vezérlõ inhalátor
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
IL232055A0 (en) Anti-htra1 antibodies and methods of use
EP2870180C0 (en) ANTI-BIOTIN ANTIBODIES AND METHODS OF USE
PT3626270T (pt) Tratamento de doenças cardiovasculares
HUE045668T2 (hu) Oldat készítmények módosított anti-IL-23p19 antitestekbõl
EP2925890C0 (en) ACCELERATED PREDICTION OF CANCER PROGRESSION AND RESPONSE TO TREATMENT
IL234606B (en) Novel methods and composition for treatment of disease
CL2014002789A1 (es) Terapia de combinación de anticuerpos anti-mif y glucocorticoides